Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707313 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 628
- Enrollment target
NCT04707313: Completed Phase 2 study, sponsored by Pfizer.
NCT04707313 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 628 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (372% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04707313, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 628 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood. This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening). There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).
Primary Outcome
Percent change from baseline in body weight at end of treatment was reported in this outcome measure. Analysis was performed using MMRM with treatment, time, strata (females versus males) and treatment-by-time interaction as fixed effects, natural log-transformed baseline as a covariate and the (natural log-transformed baseline)-by-time interaction with time fitted as a repeated effect and participant as a random effect. Values were back-transformed from the log scale. Percent change = 100 multi
Interventions
- DRUG Placebo (Cohorts 1 and 2)
- DRUG PF-06882961 (Cohorts 1 and 2)
- DRUG Placebo (Cohort 3)
- DRUG PF-06882961 (Cohort 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 2 |
What the finished NCT04707313 record still lists
NCT04707313 is an interventional study that assigns participants to a tested intervention. The registered 628 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (372% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo (Cohorts 1 and 2) is the first listed.
NCT04707313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04707313 about?
NCT04707313 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a l...
What is the current status of trial NCT04707313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 628 participants. The study started on 2021-01-29. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT04707313?
The interventions under investigation include: Placebo (Cohorts 1 and 2) (DRUG), PF-06882961 (Cohorts 1 and 2) (DRUG), Placebo (Cohort 3) (DRUG), PF-06882961 (Cohort 3) (DRUG).
Who is sponsoring clinical trial NCT04707313?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04707313's enrollment target sits among peer trials
628 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI